Ivermectin is cheap and is no longer on patent. One supposed complaint against the meta-analysis on Ivermectin was that it was "too small." Yet there were almost 18,500 people involved in the 56 studies included. Remdesivir, still on patent and costing 1500-3000 dollars, I believe, had under 1100 people in its (one) study for Covid. But …
Ivermectin is cheap and is no longer on patent. One supposed complaint against the meta-analysis on Ivermectin was that it was "too small." Yet there were almost 18,500 people involved in the 56 studies included. Remdesivir, still on patent and costing 1500-3000 dollars, I believe, had under 1100 people in its (one) study for Covid. But there won't be a provisional waiver on a vaccine if there is adequate, approved, and available treatments. Pharmaceuticals are making bank on these vaccines.
Ivermectin is cheap and is no longer on patent. One supposed complaint against the meta-analysis on Ivermectin was that it was "too small." Yet there were almost 18,500 people involved in the 56 studies included. Remdesivir, still on patent and costing 1500-3000 dollars, I believe, had under 1100 people in its (one) study for Covid. But there won't be a provisional waiver on a vaccine if there is adequate, approved, and available treatments. Pharmaceuticals are making bank on these vaccines.
They sure are.